VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment

BACKGROUND: Targeting tumor vasculature is a strategy with great promise in the treatment of many cancers. However, anti-angiogenic reagents that target VEGF/VEGFR2 signaling have met with variable results clinically. Among the possible reasons for this may be heterogeneous expression of the target...

Descripción completa

Detalles Bibliográficos
Autores principales: Patten, Steven G, Adamcic, Una, Lacombe, Kristen, Minhas, Kanwal, Skowronski, Karolina, Coomber, Brenda L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3009683/
https://www.ncbi.nlm.nih.gov/pubmed/21159176
http://dx.doi.org/10.1186/1471-2407-10-683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3009683/
https://www.ncbi.nlm.nih.gov/pubmed/21159176
http://dx.doi.org/10.1186/1471-2407-10-683

Ejemplares similares